Tetraphase Pharmaceuticals (NASDAQ:TTPH) had its target price decreased by research analysts at Piper Jaffray Companies from $6.00 to $4.00 in a research report issued on Friday, The Fly reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ price target would indicate a potential upside of 183.69% from the stock’s previous close. Piper Jaffray Companies also issued estimates for Tetraphase Pharmaceuticals’ Q1 2020 earnings at ($0.42) EPS, Q2 2020 earnings at ($0.42) EPS, Q3 2020 earnings at ($0.41) EPS and Q4 2020 earnings at ($0.43) EPS.

Other research analysts have also recently issued reports about the company. Robert W. Baird reissued a “buy” rating and issued a $3.00 target price on shares of Tetraphase Pharmaceuticals in a research report on Monday, January 7th. B. Riley assumed coverage on Tetraphase Pharmaceuticals in a research report on Friday, January 4th. They set a “buy” rating and a $3.00 price objective on the stock. Finally, Zacks Investment Research raised Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 23rd. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $4.54.

Shares of NASDAQ:TTPH opened at $1.41 on Friday. The stock has a market capitalization of $75.61 million, a price-to-earnings ratio of -0.54 and a beta of 2.99. Tetraphase Pharmaceuticals has a 52-week low of $1.01 and a 52-week high of $4.49.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Thursday, March 14th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.40). The business had revenue of $4.28 million for the quarter, compared to analysts’ expectations of $2.23 million. Tetraphase Pharmaceuticals had a negative return on equity of 65.89% and a negative net margin of 432.40%. As a group, equities analysts anticipate that Tetraphase Pharmaceuticals will post -1.39 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the company. Canada Pension Plan Investment Board lifted its position in shares of Tetraphase Pharmaceuticals by 400.0% during the 3rd quarter. Canada Pension Plan Investment Board now owns 250,000 shares of the biopharmaceutical company’s stock valued at $690,000 after buying an additional 200,000 shares in the last quarter. Marshall Wace LLP purchased a new position in shares of Tetraphase Pharmaceuticals during the 3rd quarter valued at about $927,000. Alambic Investment Management L.P. lifted its position in shares of Tetraphase Pharmaceuticals by 392.6% during the 3rd quarter. Alambic Investment Management L.P. now owns 87,704 shares of the biopharmaceutical company’s stock valued at $242,000 after buying an additional 69,900 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Tetraphase Pharmaceuticals by 14.4% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,517,623 shares of the biopharmaceutical company’s stock valued at $6,949,000 after buying an additional 317,210 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Tetraphase Pharmaceuticals by 40.0% during the 3rd quarter. Renaissance Technologies LLC now owns 873,227 shares of the biopharmaceutical company’s stock valued at $2,410,000 after buying an additional 249,342 shares in the last quarter. 44.12% of the stock is currently owned by hedge funds and other institutional investors.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Featured Story: Day Trading

The Fly

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.